Axsome Therapeutics Inc.
Axsome Therapeutics Acquires Balipodect for Neuropsychiatric Treatments
Summary
Axsome Therapeutics, Inc. has acquired exclusive global rights to balipodect, a selective PDE10A inhibitor, from Takeda for the treatment of schizophrenia and Tourette syndrome. This acquisition expands Axsome's CNS portfolio and positions the company to initiate Phase 3 trial-enabling activities for schizophrenia in 2026. Balipodect has shown a favorable safety profile in over 360 individuals across clinical studies. Axsome obtained worldwide commercial, development, and manufacturing rights to balipodect, with Takeda receiving an upfront payment and potential additional payments based on development and commercial milestones.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement